Actively Recruiting

Age: 18Years +
All Genders
ID07249775

AI-Driven Early Detection of Cachexia in Pancreatic Cancer and Feasibility of Diet and Exercise Interventions

Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-01-28

120

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

H

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

F

Florida Cancer Innovation Fund

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating a multimodal artificial intelligence (AI) model for the early detection of cancer-associated cachexia in patients with pancreatic cancer. This observational study also aims to assess how feasible and acceptable diet and exercise interventions are for managing cachexia. The study will analyze both retrospective data from the Florida Pancreas Collaborative and prospective data from newly diagnosed patients at Moffitt Cancer Center. Participants include patients with newly diagnosed pancreatic adenocarcinoma at various stages, along with oncology clinicians involved in their care. The study involves baseline lifestyle and symptom assessments using dietary questionnaires, quality of life and symptom surveys, physical activity surveys, functional fitness tests, DEXA scans, and blood draws. Extended monitoring includes wearable devices such as Fitbit, diet and activity preference surveys at 9 months, and a one-time survey to assess the integration of diet and exercise into clinical practice. During the study, participants will complete surveys and wear activity monitors for up to 9 months to track quality of life, physical activity changes, and adherence to wearable devices. Researchers will evaluate the AI model's performance and survey completion rates. The study also monitors physical fitness and health status through tests and questionnaires to better understand cachexia management. This involvement helps gather comprehensive data on patient health and the practicality of lifestyle interventions in pancreatic cancer care.

CONDITIONS

Brief Title

A First-in-Human Study of FID-022 in Solid Tumor Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histologically or cytologically confirmed diagnosis of pancreatic exocrine malignancy or clinical features highly suggestive of it with confirmation expected early in the study
  • Presentation consistent with resectable, borderline resectable, local, locally advanced, or metastatic disease
  • May have had surgery or not
  • Treatment plan likely includes systemic therapy for pancreatic cancer
  • ECOG performance status of 0 to 2
  • Able to tolerate oral intake and not currently receiving enteral or parenteral nutrition
  • Able to read and speak English
  • Able to provide written informed consent
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding at enrollment
  • Current use of tube feeding or total parenteral nutrition
  • Presence of ascites or signs of decompensated disease
  • History or evidence of bowel obstruction or gastrointestinal conditions limiting food intake
  • Severe or uncontrolled psychiatric illness that would interfere with participation
  • Other uncontrolled illnesses (e.g., infection, heart failure, liver failure) interfering with study adherence

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Baseline Lifestyle and Symptom Assessment

Duration - 1 day

Participants complete dietary, symptom, quality of life, and physical activity surveys, undergo functional fitness tests, DEXA scans, and blood draws.

1 baseline visit (in-person)

Extended Lifestyle Monitoring

Duration - Up to 9 months

Participants wear a Fitbit to monitor activity and complete a diet and physical activity preference survey at 9 months.

Continuous wearable monitoring with surveys at 9 months

Feasibility Survey

Duration - 1 day

Participants complete a one-time survey assessing the integration of diet and exercise interventions into clinical workflow.

1 survey visit (can be remote or in-person)

Trial Site Locations

Total: 1 location

1

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

Loading map...

Research Team

S

Sanjukta Bhattacharjee

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabe...

Metastatic Sarcoma

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here